"MIRX002" Achieves Primary Endpoint in Phase I Clinical Trial for Malignant Pleural Mesothelioma

PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara; hereinafter "the Company") is pleased to announce the completion of both the Single Ascending Dose (SAD) study (Protocol No.: MIRX002-01) and the Multiple Ascending Dose (MAD) study (Protocol No.: MIRX002-02), investigator-initiated clinical trials for malignant pleural mesothelioma using natural-type microRNA replacement therapy, for which the Company supplied the investigational medical product. Both studies achieved their respective primary endpoints of safety and tolerability. 

MIRX002_PressRelease_20260527.pdf

Download PDF • 129KB